on ABL DIAGNOSTICS (EPA:ABLD)
ABL Diagnostics: Growth and Outlook for 2026
ABL Diagnostics, specializing in molecular diagnostics, unveils its roadmap for 2026. The company anticipates significant growth, with projected revenue of 12.2 million euros, representing a 76.5% increase compared to 2025.
Invest Securities confirms its buy recommendation, raising the target price to 8.7 euros, due to solid fundamentals and active development drivers.
HIV genotyping and sequencing activities are central to this dynamic, while new initiatives are also contributing to growth. A significant increase in services, kits, and software is expected.
ABL Diagnostics relies on innovative solutions and strategic partnerships to strengthen its competitiveness and visibility, despite a constrained market.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABL DIAGNOSTICS news